COMMUNIQUÉS West-GlobeNewswire

How to Tell Whether an E-commerce Brand Has Outgrown Its In-House Customer Support
09/10/2026
Transcom's Retail Peak Resilience Index finds cost per order can triple while order volume doubles in operating models tuned to an average week Promotion backlogs, coverage gaps and routine contacts crowding out [...]
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
09/10/2026
WELTRUZA ™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophrenia in adults with [...]
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/10/2026
BEDFORD, Mass., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today [...]
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
09/10/2026
Denifanstat showed continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks, including 57% IGA success, 72% reduction in total lesions, and 77% reduction in inflammatory lesions, and [...]
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference
09/10/2026
MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]
Trillium Dental’s Dr. Mark Northcott Reveals Which Halloween Treats Damage Kids’ Teeth and Which Are Surprisingly Safe
09/10/2026
OTTAWA, Ontario, Oct. 09, 2026 (GLOBE NEWSWIRE) -- With Halloween approaching, Dr. Mark Northcott, co-founder of Trillium Dental and a Doctor of Dental Surgery from McGill University and Yale University, is advising [...]
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
09/10/2026
Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO ® Agreement provides Profound with [...]
Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
09/10/2026
Dutch Cardiovascular Investigator Network (WCN) Leads European Enrollment in Phase 3 Study Evaluating Etripamil Nasal Spray for AFib-RVR MONTREAL and CHARLOTTE, N.C., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Milestone ® [...]
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
09/10/2026
Fort Lee, NJ, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the [...]
Nextech Unveils Agentic AI Capabilities for Patient Experience through Partnerships with Assort Health and EliseAI
09/10/2026
Specialty practices gain a choice of two leading AI patient access platforms, unveiled at AAO 2026 in New Orleans TAMPA, Fla., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Nextech , a leading technology partner for specialty [...]
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
09/10/2026
Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment options remain limited New analyses from the ARRECTOR and DERMIS-1/2 trials [...]
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
09/10/2026
VANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
09/10/2026
Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO Keith R. Fandrick, Ph. [...]
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
09/10/2026
AUSTIN, Texas, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of [...]
New Study Shows Cortical Disarray Measurement (CDM®) Can Reflect Microscopic Patterns of Pathology in Frontotemporal Dementia
09/10/2026
Research presented at ISFTD 2026 connects measurements from the living brain with disease patterns confirmed through postmortem analysis OXFORD, United Kingdom, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Oxford Brain Diagnostics [...]
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
09/10/2026
Veteran retina commercial leader, who has helped launch BEOVU®, EYLEA® and EYLEA® HD, to lead U.S. commercialization of LYTENAVA™ (bevacizumab-vikg) ISELIN, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, [...]
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
09/10/2026
- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target of <130 [...]
NTG Nordic Transport Group A/S - Q3 2026 Conference Call
09/10/2026
NTG Nordic Transport Group A/S – Q3 2026 Conference Call We expect to release the Q3 2026 interim results of NTG Nordic Transport Group on the evening of November 9, 2026. A webcast and conference call will be held on [...]
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
09/10/2026
– Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral therapy for moderate-to-severe plaque psoriasis – Patients switching [...]

Pages